Quick answers
- What is Erzofri extended-release?
- Erzofri extended-release is a brand name of Paliperidone palmitate, a prescription medicine. The FDA NDC Directory lists 6 Erzofri extended-release products in 6 strengths and forms.
- Who makes Erzofri extended-release?
- Luye Innomind Pharma holds the FDA application for Erzofri extended-release (NDA216352, approved July 26, 2024).
- Is there a generic or store brand of Erzofri extended-release?
- Yes. The FDA NDC Directory lists 5 other products with the same active ingredients, strength and form as a Erzofri extended-release product. Ask your pharmacist whether one is right for you.
- Has Erzofri extended-release been recalled?
- No recall linked to Erzofri extended-release products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Erzofri extended-release is
Each Erzofri extended-release product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Paliperidone palmitate · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| paliperidone palmitate 117 mg/0.75 mL injection (intramuscular) | Erzofri extended-release | 1 product, 1 company | DailyMed |
| paliperidone palmitate 156 mg/mL injection (intramuscular) | Erzofri extended-release | 1 product, 1 company | DailyMed |
| paliperidone palmitate 234 mg/1.5 mL injection (intramuscular) | Erzofri extended-release | 1 product, 1 company | DailyMed |
| paliperidone palmitate 351 mg/2.25 mL injection (intramuscular) | Erzofri extended-release | None listed | DailyMed |
| paliperidone palmitate 39 mg/0.25 mL injection (intramuscular) | Erzofri extended-release | 1 product, 1 company | DailyMed |
| paliperidone palmitate 78 mg/0.5 mL injection (intramuscular) | Erzofri extended-release | 1 product, 1 company | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Paliperidone palmitate →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA216352 | Luye Innomind Pharma | July 26, 2024 | 6 |
Companies that list Erzofri extended-release
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Erzofri extended-release products.
- Shandong Luye Pharmaceutical Co., Ltd.6 products
Recalls
No recall linked to Erzofri extended-release products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.